UnknownPHASE1, PHASE2NCT05075681

Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chinese PLA General Hospital
Principal Investigator
Daihong Liu
Chinese PLA General Hospital
Intervention
Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide(drug)
Enrollment
50 enrolled
Eligibility
12-65 years · All sexes
Timeline
20212025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05075681 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials